Octreotide Administration Guidelines

Intravenous Administration

• Octreotide can be administered as an IV bolus (50 μg) followed by continuous infusion (50 μg/hour) when mixed with normal saline for gastrointestinal bleeding 1
• For management of malignant bowel obstruction, octreotide can be given as a continuous infusion when mixed with compatible IV solutions 2
• When treating hepatorenal syndrome, octreotide can be administered intravenously at 200 μg three times daily, often mixed with normal saline 3

Perioperative Administration

• For perioperative prevention of carcinoid crisis, octreotide can be administered via constant intravenous infusion at 50 μg per hour when mixed with normal saline, starting 12 hours before and continuing 24-48 hours after surgical intervention 4
• Short-acting octreotide should always be available during procedures for patients with neuroendocrine tumors, administered as bolus intravenous doses of 100-500 μg when needed 4

Specific Clinical Applications

• For chemotherapy-induced diarrhea, octreotide can be administered subcutaneously at doses of 100-500 μg three times daily, typically without mixing 5, 6
• For radiation therapy-induced diarrhea, octreotide can be given subcutaneously at 100 μg three times daily without dilution 6

Important Considerations

• When administering octreotide as a continuous infusion, standard compatibility principles with other IV medications should be followed 1
• For patients requiring long-term octreotide therapy, the long-acting release (LAR) formulation can be considered after establishing optimal dosing with the short-acting formulation 6

Cautions

• Monitor for common side effects including nausea, vomiting, abdominal pain, headache, and hyperglycemia 1